Core Viewpoint - Amgen is experiencing significant momentum, trading near 52-week highs with an 8% increase in the latest session, indicating strong institutional interest [1] Financial Performance - In Q4 2025, Amgen reported total revenues of approximately $9.9 billion, reflecting a 9% increase, while full-year revenues reached about $36.8 billion, up 10% [2] - Over the last three months, Amgen's stock has risen about 13.7%, and it is up roughly 11% year-to-date, showcasing steady accumulation in a $193 billion company [3] Stock Breakout Significance - The breakout to a 52-week high signals momentum capital attraction and a self-reinforcing setup, supported by a revenue growth rate of 10% for a mature biopharma franchise [4] - Amgen's valuation is reasonable, trading at a forward P/E of 15.6x, suggesting that the market is beginning to recognize the sturdiness of its forward earnings path [7] Product Portfolio and Pipeline - Amgen's strength lies in its diverse portfolio of therapies across various therapeutic areas, including inflammation, oncology, and rare diseases, with established products like Enbrel and newer assets contributing to growth [6] - The company is focused on expanding its growth engine beyond legacy products, with the pipeline providing optionality and commercial execution driving cash generation [12] Earnings and Valuation - Current-year EPS is approximately $22.33, with next-year EPS expected to be around $22.92, indicating consistent performance rather than hypergrowth [8] - The market is currently valuing Amgen at a mid-teens forward multiple despite delivering double-digit revenue growth, highlighting a potential mismatch that could lead to a breakout [9] Analyst Sentiment and Price Targets - Recent analyst upgrades reflect improving sentiment, with RBC raising its target to $360, Goldman Sachs to $415, and Cantor Fitzgerald to $350, indicating a consensus on Amgen's growth potential [10] Future Catalysts - Key catalysts include continued portfolio expansion and pipeline progress, which are essential for maintaining revenue growth and profitability [12] - The relative attractiveness of Amgen compared to mega-cap tech stocks, with a forward P/E of 15.6x, presents a favorable risk/reward profile [15] Conclusion - Amgen's stock hitting 52-week highs is a bullish indicator supported by strong fundamentals, reasonable valuation, and multiple growth catalysts, positioning it as a core large-cap healthcare winner [16][17]

Core Viewpoint - AeroVironment's stock has been on a downward trend, influenced by the recent selling actions of Ark Invest's ETFs, leading to a significant drop in share price [1][6]. Group 1: Stock Performance - AeroVironment shares closed down 5.3%, recovering slightly from an earlier decline of 6.8% [2]. - The stock has consistently closed lower each day this week, indicating a bearish trend [1]. Group 2: Ark Invest's Actions - Ark Invest sold shares of AeroVironment from two of its ETFs: 1,129 shares from the Ark Space Exploration & Innovation ETF and 3,886 shares from the Ark Autonomous Technology & Robotics ETF [4]. - Despite the sales, AeroVironment remains a significant holding in both ETFs, with an 8.3% weighting in the Ark Space Exploration & Innovation ETF and a 5.1% weighting in the Ark Autonomous Technology & Robotics ETF [5]. Group 3: Valuation Concerns - AeroVironment shares are currently valued at a high forward P/E ratio of 188, raising concerns about the stock being a bargain for investors [6]. - The Motley Fool Stock Advisor has identified ten stocks that they believe are better investment opportunities than AeroVironment [7].